PROCEPT BioRobotics Corporation Announces Cigna Adds Aquablation Therapy to its Coverage Policy
28 9월 2021 - 8:00PM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today announced a new positive
coverage decision from Cigna, expanding access to Aquablation
therapy for the treatment of their members with Benign Prostatic
Hyperplasia. The revised policy is effective September 15, 2021.
Cigna Corporation is a global health service company that
provides health insurance coverage for approximately 16 million
members in the United States. Their mission is to improve the
health, well-being, and peace of mind to those they serve by making
health care simple, affordable, and predictable.
“We are pleased with Cigna’s decision to cover Aquablation
therapy for the treatment of lower urinary tract symptoms (LUTS)
due to BPH. This coverage update will provide access to an
effective, safe and durable treatment option to millions of members
nationwide,” said Reza Zadno, President and CEO of Procept
BioRobotics. “Payors continue to rely on high quality clinical data
when establishing coverage criteria for new treatments, Aquablation
therapy is the only BPH surgical treatment with proven clinical
outcomes, independent of the size or the shape of the prostate, and
a reduced risk of sexual side effects. With this updated policy,
Cigna joins Medicare and numerous private health plans that cover
Aquablation therapy.”
Cigna’s Updated Benign Prostatic Hyperplasia coverage policy can
be found here: Cigna's BPH Coverage Policy
About PROCEPT BioRobotics CorporationPROCEPT is
a surgical robotics company focused on advancing patient care by
developing transformative solutions in urology. PROCEPT develops,
manufactures and sells the AquaBeam Robotic System, an advanced,
image-guided, surgical robotic system for use in minimally-invasive
urologic surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
designed Aquablation therapy to deliver effective, safe and durable
outcomes for males suffering from lower urinary tract symptoms, or
LUTS, due to BPH that are independent of prostate size and shape or
surgeon experience. PROCEPT has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 100 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Forward Looking StatementsThis release contains
forward‐looking statements within the meaning of federal securities
laws, including statements regarding the potential utilities,
values, benefits and advantages of Aquablation® therapy performed
using PROCEPT’s products, including AquaBeam® Robotic System, which
involve risks and uncertainties that could cause the actual results
to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. Forward‐looking
statements should not be read as a guarantee of future performance
or results and may not necessarily be accurate indications of the
times at, or by, which such performance or results will be
achieved. These forward‐looking statements are based on PROCEPT’s
current expectations and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward‐looking
statements as a result of these risks and uncertainties. These
risks and uncertainties are described more fully in the section
titled “Risk Factors” in PROCEPT’s filings with the Securities and
Exchange Commission (the “SEC”), including PROCEPT’s Registration
Statement on Form S-1 filed with the SEC. PROCEPT does not
undertake any obligation to update forward‐looking statements and
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward‐looking statements
contained herein. These forward-looking statements should not be
relied upon as representing PROCEPT’s views as of any date
subsequent to the date of this press release.
Investor Contact:Gilmartin GroupMatt Bacso,
CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024